Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

Table 3 Diagnoses and procedures in incident GnRH agonist users, comparing those with and without a diagnosis of prostate cancer in the SEER tumor registries

Diagnoses and procedures in incident GnRH agonist usersa
	SEER group^b		Non-SEER group^c
	n	%	n^d	%	p-value^e
Procedures related to diagnosis and histologic confirmation of prostate cancer ^a
Hospitalization	3691	21.2	338	19.9	0.75
Transurethral resection of prostate	1504	8.7	56	3.3	0.08
Prostate Biopsy	13728	79.0	1153	67.8	0.01
Transrectal Ultrasound	10342	59.5	868	51.1	0.11
Radical Prostatectomy	766	4.4	51	3.0	0.47
Any of the above	15122	87.0	1204	70.8	<0.01
Other treatment/work-up ^a
Radiation Therapy	3156	18.2	85	5.0	<0.01
CT scan/MRI pelvis	6421	36.9	503	29.6	0.16
Bone Scan	11048	63.6	910	53.5	0.06

^aWithin 3 months before or after diagnosis of prostate cancer (date based on Medicare claims)
^bDiagnosis of prostate cancer registered in SEER
^cDiagnosis of prostate cancer from Medicare claims, but not in SEER and excluding men who may have had a delay in reporting, moved out of the SEER area at the time of diagnosis or failed the SEER to Medicare linkage
^dSample sizes inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
^eChi-square test for comparison of proportions between SEER and non-SEER group, based on uninflated sample sizes
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-Results

ISSN: 1472-6963